

David W Hillman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2643094/publications.pdf>

Version: 2024-02-01

25
papers

732
citations

1163117

8
h-index

940533

16
g-index

25
all docs

25
docs citations

25
times ranked

1346
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	2.8	11
2	Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). <i>Journal of Urology</i> , 2021, 206, 319-324.	0.4	1
3	Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity. <i>International Journal of Particle Therapy</i> , 2021, 8, 41-50.	1.8	5
4	Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 31, 34-41.	1.7	4
5	Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men. <i>Prostate</i> , 2020, 80, 51-56.	2.3	5
6	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4184-4193.	1.6	74
7	Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3042-3050.	1.6	60
8	N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 613-622.	2.5	0
9	Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 411-418.	3.9	32
10	Roles of kallikrein-2 biomarkers (free-hk2 and pro-hk2) for predicting prostate cancer progression-free survival. <i>Journal of Circulating Biomarkers</i> , 2017, 6, 184945441772015.	1.3	8
11	Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T+L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 502-502.	1.6	22
12	Whole blood mRNA expression for prognosis of metastatic clear cell renal carcinoma (mCCRCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 500-500.	1.6	0
13	Association of Wnt pathway activation with prechemotherapy abiraterone acetate resistance in metastatic castration-resistant prostate cancer (mCRPC) by genome-wide analysis of metastases.. <i>Journal of Clinical Oncology</i> , 2017, 35, 175-175.	1.6	1
14	Circulating tumor cells (CTCs) and plasma cell free DNA (cfDNA) androgen receptor amplification (ARamp)-based prognosis in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 152-152.	1.6	0
15	Prognostic value of histopathology, stromal tumor infiltrating lymphocytes (sTILs) and adjuvant chemotherapy (AdjCT) in early stage triple negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 533-533.	1.6	0
16	Genome-wide analysis of metastases to reveal association of pathway activation with abiraterone acetate/prednisone (AA/P) primary resistance and cell cycle proliferation pathway activation with response duration in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5053-5053.	1.6	1
17	Whole blood androgen receptor (AR) variant (ARV12, ARV14) expression and overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5058-5058.	1.6	0
18	Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1097.	4.1	22

#	ARTICLE	IF	CITATIONS
19	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042.	1.6	315
20	Association of androgen receptor V9 (ARV9) mRNA expression in metastatic tissue with early resistance to pre-chemotherapy abiraterone acetate/prednisone (AA/P).. <i>Journal of Clinical Oncology</i> , 2016, 34, 237-237.	1.6	1
21	Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5036-5036.	1.6	0
22	Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).. <i>Journal of Clinical Oncology</i> , 2014, 32, 647-647.	1.6	2
23	N0937(Alliance): Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 1059-1059.	1.6	0
24	The radial distance of extraprostatic extension of prostate carcinoma. , 1999, 85, 2630-2637.		134
25	The radial distance of extraprostatic extension of prostate carcinoma. <i>Cancer</i> , 1999, 85, 2630-2637.	4.1	34